Literature DB >> 16374224

Lifestyle characteristics among participants in a Norwegian colorectal cancer screening trial.

Inger K Larsen1, Tom Grotmol, Kari Almendingen, Geir Hoff.   

Abstract

The aim of the present study was to evaluate to what extent lifestyle-related variables predict participation for flexible sigmoidoscopy (FS) screening when the compliance is relatively high. During 2001, a randomized sample of 6961 men and women, born between 1946 and 1950, were invited to have a flexible sigmoidoscopy screening examination. Attendees (n = 4111) were asked to fill in a questionnaire focusing on physical activity, body weight, smoking habits and diet. The questionnaire was sent by mail to non-attendees (n = 2628) and a randomized corresponding control group not invited to screening (n = 7000). Sixty-one percent attended for screening. The questionnaire response rate among attendees, non-attendees and controls was 97, 11 and 61%, respectively. Attendees were more physically active (P < 0.001), and showed more adherence to general dietary recommendations, compared with controls. Opposing their healthy exercise and dietary habits, however, attendees were more likely to be moderate smokers compared with controls. The present offer of FS screening, achieving a relatively high compliance rate, may have reached attendees using screening as a supplement to an already healthy lifestyle, but also those who seek amelioration through health checks for risks behaviour that they are perfectly well aware of, such as smoking.

Entities:  

Mesh:

Year:  2006        PMID: 16374224     DOI: 10.1097/01.cej.0000186636.27496.bb

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  7 in total

1.  Do individuals with a family history of colorectal cancer adhere to medical recommendations for the prevention of colorectal cancer?

Authors:  Karen Bronner; Ilse Mesters; Ahuva Weiss-Meilnik; Ravit Geva; Guy Rozner; Hana Strul; Moshe Inbar; Zamir Halpern; Revital Kariv
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

2.  The influence of non-response in a population-based cohort study on type 2 diabetes evaluated by the Swedish Prescribed Drug Register.

Authors:  Anna-Karin Eriksson; Anders Ekbom; Agneta Hilding; Claes-Göran Ostenson
Journal:  Eur J Epidemiol       Date:  2011-11-17       Impact factor: 8.082

3.  Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial.

Authors:  Geir Hoff; Tom Grotmol; Eva Skovlund; Michael Bretthauer
Journal:  BMJ       Date:  2009-05-29

4.  Lifestyle as a predictor for colonic neoplasia in asymptomatic individuals.

Authors:  Inger K Larsen; Tom Grotmol; Kari Almendingen; Geir Hoff
Journal:  BMC Gastroenterol       Date:  2006-01-13       Impact factor: 3.067

5.  Lifestyle predictors for non-participation and outcome in the second round of faecal immunochemical test in colorectal cancer screening.

Authors:  Markus Dines Knudsen; Paula Berstad; Anette Hjartåker; Elisabeth Haagensen Gulichsen; Geir Hoff; Thomas de Lange; Tomm Bernklev; Edoardo Botteri
Journal:  Br J Cancer       Date:  2017-07-13       Impact factor: 7.640

6.  Low-intensity self-management intervention for persons with type 2 diabetes using a mobile phone-based diabetes diary, with and without health counseling and motivational interviewing: protocol for a randomized controlled trial.

Authors:  Lis Ribu; Heidi Holmen; Astrid Torbjørnsen; Astrid Klopstad Wahl; Astrid Grøttland; Milada Cvancarova Småstuen; Elisabeth Elind; Trine Strand Bergmo; Elin Breivik; Eirik Arsand
Journal:  JMIR Res Protoc       Date:  2013-08-26

7.  A Low-Intensity Mobile Health Intervention With and Without Health Counseling for Persons With Type 2 Diabetes, Part 1: Baseline and Short-Term Results From a Randomized Controlled Trial in the Norwegian Part of RENEWING HEALTH.

Authors:  Astrid Torbjørnsen; Anne Karen Jenum; Milada Cvancarova Småstuen; Eirik Arsand; Heidi Holmen; Astrid Klopstad Wahl; Lis Ribu
Journal:  JMIR Mhealth Uhealth       Date:  2014-12-11       Impact factor: 4.773

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.